Background: Clinical trials have demonstrated rapid antidepressant effects with intravenous
(IV) ketamine for major depressive disorder, with relatively less research specifically for …

Background A single low-dose ketamine infusion exhibited a rapid antidepressant effect
within 1 h. Despite its short biological half-life (approximately 3 h), the antidepressant effect …

Objective To evaluate the safety, tolerability, and effectiveness of repeated doses of
intravenous (IV) ketamine in older adults (ie,≥ 60 years of age) with treatment-resistant …

Background Clinical and animal studies have reported conflicting results regarding the effect
of ketamine on cognitive function, although increasing evidence supports a rapid and …

Objective Ketamine has demonstrated rapid and significant antidepressant effects in
patients with treatment resistant depression (TRD). Herein, we conducted a systematic …

Major depressive disorder (MDD) is a serious psychiatric illness that causes functional
impairment in many people. While monoaminergic antidepressants have been used to …

Currently available drugs for unipolar major depressive disorder (MDD), which target
monoaminergic systems, have a delayed onset of action andsignificant limitations in …

Ketamine is a dissociative anesthetic agent used routinely for more than 40 years in human
anesthesiology (7). It is particularly useful in conditions in which cardiovascular and …

Introduction Ketamine can produce rapid-acting antidepressant effects. Esketamine
(Spravato), the S-enantiomer of racemic ketamine, was approved by the FDA for treatment …

Background Depressive disorders are a common form of psychiatric illness and cause
significant disability. Regulation authorities, the medical profession and the public require …